PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-14.34%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-7.72%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-7.72%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
D&A reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency.
7.65%
EBITDA growth exceeding 1.5x TRVN's 1.27%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
7.72%
Operating income growth 1.25-1.5x TRVN's 5.20%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
158.44%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
12.50%
Pre-tax income growth exceeding 1.5x TRVN's 1.36%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Net income growth exceeding 1.5x TRVN's 1.36%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
15.94%
EPS growth exceeding 1.5x TRVN's 3.85%. David Dodd would verify competitive advantages.
15.94%
Diluted EPS growth exceeding 1.5x TRVN's 3.85%. David Dodd would verify competitive advantages.
4.10%
Share count reduction below 50% of TRVN's 2.61%. Michael Burry would check for concerns.
4.10%
Diluted share reduction below 50% of TRVN's 2.61%. Michael Burry would check for concerns.